AntiRadical Therapeutics

AntiRadical Therapeutics LLC is a preclinical-stage biotech focused on developing novel anti-aging drugs based on stable nitroxide free radicals. Its lead candidate, DETOPS, is positioned as a next-generation therapy targeting oxidative stress, cellular signaling, and vascular dynamics to address age-related conditions like neurodegenerative and cardiovascular diseases. The company is private, pre-revenue, and appears to be in the early stages of validating its platform and advancing its lead program through preclinical development.

Platform based on stable nitroxide free radicals, designed as next-generation molecules with enhanced stability. They function not only as antioxidants (mimicking superoxide dismutase) but are proposed to modulate nitric oxide pathways, cellular signaling, and vascular dynamics to target fundamental aging processes.

ART competes in the emerging longevity therapeutics space, which includes companies developing senolytics (e.g., Unity Biotechnology), mTOR inhibitors (e.g., resTORbio), mitochondrial therapies, and other geroprotective mechanisms. Its direct competition includes other firms exploring nitroxides or similar redox-modulating compounds, but its claim of enhanced stability aims to differentiate from first-generation molecules like TEMPOL.